Author of

• 15209

  +

  P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15210

    +

    P3.01-001 - Imprime PGG, a Novel Innate Immune Modulator, Combined with Carboplatin, Paclitaxel and Bevacizumab for 1st Line Advanced Nonsquamous NSCLC (ID 3005)

    09:30 - 09:30  |  Author(s): W. Engel-Reidel
    • Abstract
    • Slides

    Background:
    Imprime PGG (PGG) in combination with carboplatin/paclitaxel chemotherapy (C/P) and bevacizumab (Bev) increased objective response rates (ORR) and overall survival (OS) of patients (pts) with previously untreated stage IV non-squamous NSCLC in comparison to C/P + Bev alone in a randomized, controlled, multicenter phase 2 trial (Engel-Riedel W et al, Ann Oncol 25 [Suppl 5], 2014, LBA32). Herein, we report landmark survival analyses at the 1- and 2-year time points. The trial was sponsored by Biothera, ClinicalTrials.gov NCT 00874107, EudraCT 2008-006780-37.
    
    Methods:
    92 pts with stage IV nonsquamous NSCLC were randomized 2:1 to receive PGG (4 mg/kg IV days 1, 8, 15 of each 3-week cycle) + C/P + Bev (PGG group) vs C/P + Bev alone (Ctrl group). C/P was administered for 4 to 6 cycles; Bev +/- PGG were administered until disease progression or intolerable toxicity. The primary endpoint was ORR based on modified RECIST v1.0 and was assessed centrally. Secondary endpoints included overall survival (OS), progression-free survival (PFS), duration of response (DoR) and safety. Imaging assessments (CT of chest and abdomen) were reviewed every 6 weeks. The primary analysis occurred after all pts had either progressed or had the opportunity to complete at least 18 treatment cycles (54 weeks).
    
    Results:
    An objective response was achieved by 29 out of 48 evaluable pts (60.4%; 1 CR, 28 PR) in the PGG group and 10 out of 23 (43.5%; 0 CR, 10 PR) in the Ctrl group (p=0.21). Median (m) OS was 16.1 mos with PGG compared to 11.6 mos (HR=0.66; p=0.13) with Ctrl. The mPFS was 11.9 mos vs 10.2 mos (HR=0.86; p=0.59), and mDoR was 10.3 mos vs 5.6 mos (HR=0.92; p=0.90) among subjects receiving PGG vs Ctrl, respectively. Survival rates of pts (95% CI) in the PGG vs Ctrl groups were 62.8% (48.8, 74.0) vs 42.7% (22.7, 61.4) at 12 mos, and 37.0% (22.5, 51.5) vs 24.4% (7.9, 45.7) at 24 mos. Overall, the incidence of adverse events (AEs) was similar across treatment groups. The most common AEs (occurring in ≥ 5 pts) deemed possibly or probably related to PGG by the investigator were chills (13.6%); dyspnea, fatigue (10.2% each); nausea, pyrexia, and infusion-related reactions (8.5% each). Overall, 37.3% of pts receiving PGG and 43.3% receiving Ctrl discontinued the study due to AEs.
    
    Conclusion:
    The addition of PGG to C/P + Bev therapy was well tolerated and resulted in clinically meaningful increases in ORR, DoR, and OS. Results did not reach statistical significance in this phase 2 study. Further investigation is warranted to confirm the efficacy and safety of this combination.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.